Use of angiopoietin-2 serum levels as a clinical surrogate for vascular normalization under bevacizumab treatment

Authors :: Clemens-Martin Wendtner
Valentin Goede
R. Schnell
Oliver Coutelle
Ulrich Hacker
Thomas C. Koslowsky
Martin R. Weihrauch
G. Kayoko
J. Neuneier
Source :: Journal of Clinical Oncology. 26:4133-4133
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 4133 Background: The combination of chemotherapy and the anti-VEGF antibody bevacizumab (BV) is the current standard treatment for advanced colorectal cancer (CRC). Previous efforts to identify bio...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Bevacizumab
biology
business.industry
Angiopoietin 2
Standard treatment
medicine.medical_treatment
Vascular normalization
Advanced colorectal cancer
Internal medicine
medicine
biology.protein
Antibody
business
medicine.drug

Full Text Access

Tools